Literature DB >> 15139495

Screening for hemochromatosis in Turkey.

Hakan Bozkaya1, Mehmet Bektas, Olga Metin, Ozlem Erkan, Dicle Ibrahimoglu, Klara Dalva, Filiz Akbiyik, Selim Gurel, Abdurrahman Mithat Bozdayi, Cemal Akay, Cihan Yurdaydin, Onder Aslan, Ozden Uzunalimoglu.   

Abstract

In this study we screened 3060 consecutive blood donors for an unbound iron-binding capacity level of <28 microM and then performed HFE mutation analysis in these subjects. Sixty-five of the 75 subjects with a low initial unbound iron-binding capacity (all had normal ferritin levels) came back and only 5 (8%) had a low fasting unbound iron-binding capacity. Mutational analysis revealed H63D heterozygosity in two of five subjects. Four of five subjects had liver biopsy indication and none had increased liver iron. HFE genotyping of 60 subjects with a low initial but normal fasting unbound iron-binding capacity revealed heterozygote H63D in seven (11.6%). No allelic variant of position 282 or 63 was found in three previously diagnosed patients with hereditary hemochromatosis. In conclusion, full phenotypic expression of hereditary hemochromatosis is very rare in Turkey. The absence of HFE mutations in three patients with hereditary hemochromatosis suggests that hereditary hemochromatosis in Turkey occurs without common HFE mutations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15139495     DOI: 10.1023/b:ddas.0000020500.26184.ce

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  41 in total

1.  Global prevalence of putative haemochromatosis mutations.

Authors:  A T Merryweather-Clarke; J J Pointon; J D Shearman; K J Robson
Journal:  J Med Genet       Date:  1997-04       Impact factor: 6.318

2.  Haemochromatosis and HLA-H.

Authors:  E C Jazwinska; L M Cullen; F Busfield; W R Pyper; S I Webb; L W Powell; C P Morris; T P Walsh
Journal:  Nat Genet       Date:  1996-11       Impact factor: 38.330

3.  Cost-effectiveness of screening for hereditary hemochromatosis.

Authors:  P D Phatak; G Guzman; J E Woll; A Robeson; C E Phelps
Journal:  Arch Intern Med       Date:  1994-04-11

4.  Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping.

Authors:  P C Adams; L S Valberg
Journal:  Am J Gastroenterol       Date:  1999-06       Impact factor: 10.864

5.  Genotypic/phenotypic correlations in genetic hemochromatosis: evolution of diagnostic criteria.

Authors:  P C Adams; S Chakrabarti
Journal:  Gastroenterology       Date:  1998-02       Impact factor: 22.682

Review 6.  Haemochromatosis in the new millennium.

Authors:  L W Powell; V N Subramaniam; T R Yapp
Journal:  J Hepatol       Date:  2000       Impact factor: 25.083

7.  A population-based study of the clinical expression of the hemochromatosis gene.

Authors:  J K Olynyk; D J Cullen; S Aquilia; E Rossi; L Summerville; L W Powell
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

8.  Screening for hemochromatosis: a cost-effectiveness study based on 12,258 patients.

Authors:  V Balan; W Baldus; V Fairbanks; V Michels; M Burritt; G Klee
Journal:  Gastroenterology       Date:  1994-08       Impact factor: 22.682

9.  Screening for haemochromatosis: prevalence among Danish blood donors.

Authors:  P Wiggers; J Dalhøj; H Kiaer; H Ring-Larsen; P H Petersen; O Blaabjerg; M Hørder
Journal:  J Intern Med       Date:  1991-09       Impact factor: 8.989

10.  Primary iron overload in African Americans.

Authors:  R K Wurapa; V R Gordeuk; G M Brittenham; A Khiyami; G P Schechter; C Q Edwards
Journal:  Am J Med       Date:  1996-07       Impact factor: 4.965

View more
  8 in total

1.  Serum iron levels and hepatic iron overload in nonalcoholic steatohepatitis and chronic viral hepatitis.

Authors:  Suleyman Uraz; Cem Aygun; Abdullah Sonsuz; Gulsen Ozbay
Journal:  Dig Dis Sci       Date:  2005-05       Impact factor: 3.199

2.  Should we screen for hereditary hemochromatosis in healthy Lebanese: a pilot study.

Authors:  Rami A R Mahfouz; Doja S Sarieddine; Khalil M Charafeddine; Rabab N Abdul Khalik; Najwa K Cortas; Rose T Daher
Journal:  Mol Biol Rep       Date:  2011-05-07       Impact factor: 2.316

3.  In the presence of autoantibodies and iron overload, do not judge a book by its cover: A case report.

Authors:  Nur Yazdali Koylu; Bahadir Koylu; Cenk Sokmensuer; Yasemin Balaban
Journal:  Hepatol Forum       Date:  2021-05-24

4.  Hereditary haemochromatosis gene (HFE) H63D mutation shows an association with abnormal sperm motility.

Authors:  Aysen Gunel-Ozcan; M Murad Basar; Ucler Kisa; Handan C Ankarali
Journal:  Mol Biol Rep       Date:  2008-10-10       Impact factor: 2.316

5.  HFE gene mutation, chronic liver disease, and iron overload In Turkey.

Authors:  Oya Yönal; Ozden Hatirnaz; Filiz Akyüz; Ugur Ozbek; Kadir Demir; Sabahattin Kaymakoglu; Atilla Okten; Zeynel Mungan
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

6.  Frequency of Two Common HFE Gene Mutations (C282Y and H63D) in a Group of Iranian Patients With Cryptogenic Cirrhosis.

Authors:  Zahra Jowkar; Bita Geramizadeh; Mahmoud Shariat
Journal:  Hepat Mon       Date:  2011-11-30       Impact factor: 0.660

7.  HFE H63D mutation frequency shows an increase in Turkish women with breast cancer.

Authors:  Aysen Gunel-Ozcan; Sibel Alyilmaz-Bekmez; Emine Nilufer Guler; Dicle Guc
Journal:  BMC Cancer       Date:  2006-02-19       Impact factor: 4.430

8.  Effect of Hereditary Hemochromatosis Gene H63D and C282Y Mutations on Iron Overload in Sickle Cell Disease Patients.

Authors:  Yunus Kasım Terzi; Tuğçe Bulakbaşı Balcı; Can Boğa; Zafer Koç; Zerrin Yılmaz Çelik; Hakan Özdoğu; Sema Karakuş; Feride İffet Şahin
Journal:  Turk J Haematol       Date:  2016-04-18       Impact factor: 1.831

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.